



Microdosing psychedelics: personality, mental health, and creativity differences in microdosers

Thomas Anderson¹ · Rotem Petranker²  · Daniel Rosenbaum³ · Cory R. Weissman^{3,4} · Le-Anh Dinh-Williams⁵ · Katrina Hui³ · Emma Hapke^{3,4} · Norman A. S. Farb¹

Received: 10 September 2018 / Accepted: 2 November 2018 / Published online: 2 January 2019
© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Abstract

Rationale Microdosing psychedelics—the regular consumption of small amounts of psychedelic substances such as LSD or psilocybin—is a growing trend in popular culture. Recent studies on full-dose psychedelic psychotherapy reveal promising benefits for mental well-being, especially for depression and end-of-life anxiety. While full-dose therapies include perception-distorting properties, microdosing may provide complementary clinical benefits using lower-risk, non-hallucinogenic doses.

Objectives This pre-registered study aimed to investigate whether microdosing psychedelics is related to differences in personality, mental health, and creativity.

Methods In this observational study, respondents recruited from online forums self-reported their microdosing behaviors and completed questionnaires concerning dysfunctional attitudes, wisdom, negative emotionality, open-mindedness, and mood. Respondents also performed the Unusual Uses Task to assess their creativity.

Results Current and former microdosers scored lower on measures of dysfunctional attitudes ($p < 0.001$, $r = -0.92$) and negative emotionality ($p = 0.009$, $r = -0.85$) and higher on wisdom ($p < 0.001$, $r = 0.88$), open-mindedness ($p = 0.027$, $r = 0.67$), and creativity ($p < 0.001$, $r = 0.15$) when compared to non-microdosing controls.

Conclusions These findings provide promising initial evidence that warrants controlled experimental research to directly test safety and clinical efficacy. As microdoses are easier to administer than full-doses, this new paradigm has the exciting potential to shape future psychedelic research.

Keywords Microdosing · Psychedelic · LSD · Psilocybin · Creativity · Dysfunctional Attitudes · Wisdom · Open Mindedness · Negative Emotionality · Preregistered

Thomas Anderson and Rotem Petranker contributed equally to this work.

- ✉ Thomas Anderson
metathomas.anderson@mail.utoronto.ca
- ✉ Rotem Petranker
rotem@boredomlab.org

- ¹ Department of Psychology, University of Toronto, Toronto, ON, Canada
- ² Department of Psychology, York University, Toronto, ON, Canada
- ³ Department of Psychiatry, University of Toronto, Toronto, ON, Canada
- ⁴ Centre for Addiction and Mental Health, Toronto, ON, Canada
- ⁵ Department of Psychology, University of Toronto Scarborough, Scarborough, ON, Canada

Introduction

Microdosing psychedelics—the practice of regularly consuming very low doses of psychedelic substances such as lysergic acid diethylamide (LSD) or psilocybin (“magic” mushrooms)—is a growing practice despite a lack of scientific research validating its effects. One online microdosing forum (/r/microdosing subreddit, Reddit Inc., San Francisco, CA, USA) has almost 40,000 subscribers and doubled its subscriber count in the past year (Fig. 1). The popular media has described the consumption of psychedelics in doses much lower than typical therapeutic doses (Fadiman 2011; Leonard 2015; Solon 2016; Waldman 2017), and articles and anecdotes claim benefits including improved mood, focus, and creativity alongside decreased symptoms of depression and anxiety. While decreased depression and anxiety are consistent with research on full-dose psychedelics (Carhart-




Fig. 1 Rise in subscribers to an online microdosing forum, [Reddit.com/r/microdosing](https://www.reddit.com/r/microdosing). As of November 2018, the subscriber count has exceeded 40,000 subscribers, doubling in less than 1 year

Harris et al. 2017; Griffiths et al. 2016), microdosing could offer these benefits without any perceptual distortions and reduced need for expensive clinical oversight typical of full-dose psychedelic psychotherapy. Nevertheless, both LSD and psilocybin are controlled substances in most countries and so members of the public enticed by purported benefits of microdosing expose themselves to the risks implied by criminalized activity. For example, in the USA, LSD and psilocybin are schedule I controlled substances, meaning that they have no accepted therapeutic use. Such risks are exacerbated by an absence of even minimal scientific evidence that normally surrounds clinical use, such as data on safety, efficacy, common side-effects, contraindications, and appropriate dose and dose schedule.

It is unlikely that normative standards for microdosing will emerge without an initial description of current microdosing practices and associated outcomes. We therefore measured self-reported practices and psychological function of participants in existing microdosing communities and compared them to control participants with no microdosing experience. This design allows for a structured description of the common practices used in microdosing from which future clinical trials can build.

Full-dose psychedelics

Interest in microdosing is likely predicated on research linking clinical benefits to full-dose psychedelic use. By 1975, over 1000 studies had linked psychedelic substance use with salutary effects on mental health and personal growth (Grinspoon and Bakalar 1979). More recent research suggests efficacy for a number of health conditions, including obsessive compulsive disorder (Moreno et al. 2006), alcohol dependence (Bogenschutz et al. 2015), tobacco dependence (Johnson et al. 2014), depression (Carhart-Harris et al. 2017; de

Osório et al. 2015), and end-of-life anxiety (Griffiths et al. 2016; Ross et al. 2016).

While research on psychedelics provides evidence for the therapeutic effects of full-doses, such experiences are often quite intense thus confer substantive participant risk. Popular vernacular includes the term “bad trip,” and, indeed, one study participant described a full-dose experience as “the worst experience of her life” (Griffiths et al. 2011). In an online survey of the worst “bad trips” experienced, 39% percent of participants rated their psychedelic experience among the top five most challenging experiences of his/her lifetime (Carbonaro et al. 2016). At the same time, Carbonaro et al. (2016) also found that despite the difficult experiences, 84% of participants reported benefitting from the experience. Although research on LSD and psilocybin suggests low risks for abuse or harmful effects (van Amsterdam et al. 2011; Halpern and Pope 1999; Johnson et al. 2018), a small percentage of users are at risk of developing persisting perceptual effects (Hallucinogen Persisting Perception Disorder; Martinotti et al. 2018) or risk of being hospitalized for acute intoxication, especially if mixed with alcohol (Hardaway et al. 2016). While large population studies suggest that psychedelics are not usually associated with detrimental mental health outcomes (Krebs and Johansen 2013), microdosing may circumvent this issue as anecdotal reports suggest numerous positive outcomes without the risks associated with acute full-dose intoxication (Fadiman 2011).

The present study

In this study, we describe the psychological profile of the growing microdosing community by making comparisons against a population of non-microdosers. We compared groups of self-described microdosers (current and former

microdosers) against controls (no microdosing experience) across a variety of mental health and personality variables. These include dysfunctional attitudes (de Graaf et al. 2009), wisdom (Glück et al. 2013), negative emotionality and open-mindedness (Soto and John 2017), and creativity (Silvia 2011). This study is part of a larger project that also reports on the demographics and psychiatric history of microdosing users (Rosenbaum et al. 2018). A qualitative report examining subjective benefits and drawbacks of microdosing is also in preparation (Anderson et al. 2018). We presently address pre-registered hypotheses about the outcomes associated with microdosing experience on validated scales.

Methods

Pre-registered hypotheses

Prior to data collection, this study was pre-registered on the Open Science Framework (OSF; <https://osf.io/ke49d/>). We define “Microdosers” as those participants with experience microdosing, whether current or former use. We pre-registered the following hypotheses:

Mental health vulnerability, wisdom, and personality

While the mechanisms driving psychedelic substances’ clinical efficacy are unclear, several psychological constructs are likely involved. These include practical indicators of flourishing, such as freedom from dysfunctional beliefs about oneself, other people, and the world; wisdom; and personality traits, especially neuroticism and openness to experiences.

Psychedelic substances are purported to have profound effects on one’s understanding of the self and world, leading to enhanced insight and personal growth (Dominguez-Clavé et al. 2016; Dos Santos et al. 2016; Kometer et al. 2015; Strassman 2016). As such, we hypothesized that microdosers would have lower dysfunctional attitudes and higher wisdom than non-microdosers. Furthermore, improved mood and reduced mental health concerns are commonly reported outcomes of microdosing online (*/r/microdosing* subreddit, Reddit Inc., San Francisco, CA, USA). For this reason, we hypothesized that microdosers would have lower negative emotionality (depression, anxiety, and emotional volatility) than non-microdosers. Finally, participants experiencing a single full dose of psilocybin showed a robust and sustained increase in openness (MacLean et al. 2011); we therefore predicted that microdosers would also have higher openness.

- **H1a** *Microdosers will have lower dysfunctional attitude scores than non-microdosers.*
- **H1b** *Microdosers will have higher wisdom scores than non-microdosers.*

- **H1c** *Microdosers will have lower negative emotionality scores than non-microdosers.*
- **H1d** *Microdosers will have higher open-mindedness scores than non-microdosers.*

Creativity

The Broaden and Build theory (Fredrickson 2004) proposes a link between positive emotions and relaxed cognitive constraints as improved well-being may recruit personal resources in the generation of creative ways of coping with challenges. Enhanced creativity is one of the commonly reported outcomes of microdosing in media reports (Solon 2016) and online (*/r/microdosing* subreddit, Reddit Inc., San Francisco, CA, USA) and is often reported as a benefit of full-dose psychedelics (Fadiman 2011).

- **H2** *Microdosers will have higher creativity scores than non-microdosers.*

Importance of benefits

Participants were asked to rate how important qualitative benefits of microdosing were to them. We used this measure of subjective “importance of benefits” as a broad outcome of participants’ positive valuation of microdosing. Based on online anecdotal reports, we predicted that there would be a total-dose response curve such that microdosers would rate the importance of benefits as quickly increasing to a plateau. Concerning dose scheduling, Fadiman (2011) proposed a dose schedule such that microdosers consume their substance 1 day, then refrain for 2 days, then dose again; we hypothesized that this schedule would show optimal reported importance of benefits compared to alternate dose frequencies, perhaps due to substance-tolerance (more frequent) or limited efficacy (less frequent).

Total doses and dose frequency

- **H3a** *A logarithmic relationship will exist between total lifetime microdoses and average reported importance of benefits. Specifically, benefits are expected to be minimal with minimal total doses, then increase, and subsequently stabilize at a plateau.*

- **H3b** *A quadratic relationship will exist between frequency of microdosing and average reported importance of benefits. Specifically, maximum benefits are expected when participants report frequency of microdoses at ~ 3 days between microdoses with reduced benefits for shorter and longer frequencies.*

More frequent and more intense positive experiences with a substance motivate future use of that substance (de Wit and Phillips 2012). As such, microdosers with a more extensive history of full-dose psychedelic use may be especially

motivated to try microdosing and may evaluate benefits of microdosing more highly. This positivity bias may extend beyond psychedelics as, more generally, substance use is associated with greater openness to experience (Gunnarsson et al. 2008; Terracciano et al. 2008; Trull and Sher 1994), which may include an openness to try novel pharmacological interventions, such as microdosing.

Substance use history

H4a *Microdosers reporting at least one life-time use of a classic psychedelic (LSD, psilocybin mushrooms, DMT, ayahuasca, mescaline) at full dose will report higher average importance of benefits than microdosers that have not had a full dose.*

H4b *Microdosers reporting greater variety of recreational substance use (“Polydrug User Experience Index,” see below) will report higher average importance of benefits than microdosers with less recreational substance experience.*

Deviations from pre-registration

A survey flow error resulted in unintended data collection on dose frequency and importance (H3 and H4) from participants with no experience microdosing; this data has been discarded.

Participants

Participants were snowball-recruited via social media (e.g., Facebook, Twitter) and recruited through posts on the online forum “reddit” (Reddit Inc., San Francisco, CA, USA): links were posted under the username /u/oredna on the following subreddits: Microdosing, Nootropics, Psychonaut, RationalPsychonaut, Tryptonaut, Drugs, LSD, shrooms, DMT, researchchemicals, and SampleSize. Both participants with experience and participants without experience microdosing psychedelics were recruited for this study. Participation was voluntary, and participants were not remunerated. The survey was in English and internationally available.

Participants exited the online survey at different stages of completion; different analyses therefore employ different numbers of participants. While 1390 respondents began the survey, 475 exited before responding, three requested that their responses be removed, and three responses were removed for disingenuous responding, i.e., “trolling”. In total, 909 participants entered enough data to be included in analyses, sorted into two categories: those with microdosing experience (microdosers: $n = 594$, 65%) and those without such experience (non-microdosers: $n = 315$, 35%); full-dose experience with psychedelics was not considered for determining microdosing status. Of these participants, 29% were currently microdosing (current microdosers), 37% had microdosed in the past but have since stopped (former microdosers), 30%

were interested in microdosing but had no prior experience, and 4% had no prior experience and reported not being interested in microdosing. Participants from 29 countries responded to the survey (median age = 26, 82% males, 70% white). For a more comprehensive breakdown, see the full epidemiological report (Rosenbaum et al. 2018).

Design and questionnaires

Following informed consent, participants completed online computer-based questionnaires (<https://osf.io/jmcrh/>) including questions pertaining to microdosing habits (substance, frequency, dosage), substance use and mental health history, dispositional personality variables (dysfunctional attitudes, wisdom, negative emotionality, open-mindedness), and a creativity task. Questions were displayed according to experience with microdosing, i.e., individuals who reported never having microdosed were not shown questions related to a history of microdosing (note survey flow error, 1.4.1 above). For uniformity, all scales were rated using a continuous 0–100 slider-scale with nominal descriptors at 0 (“Disagree Strongly”) and 100 (“Agree Strongly”) (Matejka et al. 2016). For brevity, methods reported here focus on variables analyzed in this paper; a complete list of all questions is available on the OSF pre-registration.

Microdosing substance

The majority of participants reported using LSD (65%) and/or psilocybin (28%) for microdosing; 16% reported using another substance. For a more comprehensive breakdown, see the full epidemiological report (Rosenbaum et al. 2018).

Mental health vulnerability

The DAS-A-17 is a short-version of the Dysfunctional Attitude Scale, a 40-item self-report scale designed to measure the presence and intensity of dysfunctional beliefs (de Graaf et al. 2009). Participants rate statements of beliefs (e.g., “If I fail at my work, then I am a failure as a person.”) on a 7-point Likert scale and the total score is the sum of the 17-items (range: 17–119) with higher scores indicating more dysfunctional attitudes (Weissman and Beck 1978). The DAS-A-17 includes a total score and two subscales: “perfectionism/performance evaluation” (11 items) and “dependency” (6 items). Reliability for total score was excellent ($\alpha = 0.91$) and good for the subscales (perf: $\alpha = 0.87$, dep: $\alpha = 0.85$).

A Mental Health Index of psychological disorders was computed as a simple binary 0/1 based on the question, “Have you ever been diagnosed by a doctor or health care professional (e.g., psychiatrist, psychologist) with any of the following diagnoses,” which was followed by a list of DSM-V diagnoses. Endorsing any diagnosis was coded as a “1,”

otherwise “None of the above” was coded as “0.” Comprehensive findings will be available in the epidemiological report (Rosenbaum et al. 2018).

Wisdom

The Brief Wisdom Screening Scale (BWSS) (Glück et al. 2013) was developed by selecting the 20 items that were most highly correlated with the common factor of “wisdom self-report” across three leading wisdom self-report measures. Reliability was good ($\alpha = 0.86$).

Personality

The Big Five Inventory 2 (BFI2) (Soto and John 2016) is an updated five-factor personality measure using the commonly recognized five-factor model: extraversion, agreeableness, conscientiousness, negative emotionality (formerly “neuroticism”), and open-mindedness (formerly openness to experience). Our hypotheses were centered on two of these subscales: negative emotionality and open-mindedness, thus only these factors were measured. Reliability was good (negative emotionality $\alpha = 0.91$, open-mindedness $\alpha = 0.79$).

Creativity

The Unusual Uses Task is a task in which participants generate creative uses for mundane objects (UUT) (Silvia 2011). The UUT instructions emphasized the importance of original responses, reading “Please try and think of the most unusual, creative, and uncommon uses you can imagine” (Harrington 1975). Participants were asked to give as many responses as they could for each of two items (brick, knife), allotted 1 min for each. During analysis, responses were split into alphabetical lists to avoid within-participant biases. Responses were rated by three independent research assistants using three dimensions: uncommon, clever, and remote (Silvia et al. 2008). Dimension-scores across objects were averaged to produce three dimension-scores. Intraclass correlation coefficient was moderate for each dimension (uncommon: 68.25, remote: 57.25, clever: 59.75) and moderate for each object (brick = 0.61, knife = 0.64).

Importance of benefits

Participants rated qualitative benefits of microdosing in terms of personal, subjective importance for three self-generated benefits. The average of these scores was then used as a broad index of participants’ subjective valuation of microdosing, analyzed in H3/4 in this study. A taxonomy that organizes the participant-generated benefits has been generated using Grounded Theory analysis and will be featured in an independent report (Anderson et al. 2018).

Microdosing frequency

Microdosers reported the total number of lifetime microdoses taken (0 to 100). They also reported dose scheduling, that is, the number of days spaced between each microdose (dose every day to dose once every 2 months).

Substance use history

To test H4 concerning substance use history, participants reported their experience with full-dose psychedelics and with other substances. We developed a novel index: the “Polydrug User Experience Index.” This novel measure was computed as the sum of recreational experiences across 13 classes of substance (e.g., alcohol, cannabis, MDMA, stimulants, opiates, and dissociatives) accounting for recency of experience. Each class of substance was scored according to the following metric: (a) used in past month: +4 points; (b) used in past year: +2 points; (c) used ever: +1 point; (d) never used: +0 points; (e) prefer not to answer: +0 points. Scores range from 0 to 52, with lower scores indicating less experience with recreational substance use.

Mood

A “valence” score was computed using a mood board (<https://osf.io/jmcrh/>) as the count of pleasant minus unpleasant items, as was an “arousal” score for high-intensity minus low-intensity moods.

Results


Pre-registered hypotheses and planned follow-up analysis

Mental health vulnerability, wisdom, and personality

Mental health vulnerability Microdosing predicted lower scores on dysfunctional attitudes ($b = -8.69$, 95% CI $[-12.48 - 4.89]$, $z(364) = -4.49$, $p < 0.001$, $r = -0.92$), even when controlling for a history of mental illness, which was also significant ($b = 5.74$, 95% CI $[2.45 - 9.03]$, $z(364) = 3.42$, $p < 0.001$, $r = 0.85$) (Fig. 2). Dysfunctional attitudes were not related to current versus former microdosing ($b = 1.90$, 95% CI $[-1.91 - 5.71]$, $p = 0.33$), nor to type of substance used (LSD vs psilocybin: $b = 0.56$, 95% CI $[-4.93 - 6.05]$, $p = 0.842$), nor to total number of lifetime microdoses ($b = -1.66$, 95% CI $[-3.47 - 0.15]$, $p = 0.074$).

Wisdom Microdosing predicted higher wisdom scores ($b = 6.61$, 95% CI $[3.52 - 9.69]$, $z(367) = 4.19$, $p < 0.001$, $r =$

Fig. 2 Differences in dysfunctional attitudes between microdosers and non-microdosers including breakdown by history of mental illness. The asterisk (*) indicates a significant main effect of microdosing status such that microdosers showed lower dysfunctional attitudes than non-microdosers ($p < 0.001$). Respondents with no history of mental illness (blue) also had lower dysfunctional attitudes than those with a history of mental illness (orange, $p < 0.001$), though microdosing status was a significant predictor even controlling for this potent covariate



0.88) when controlling for age and level of education, which were not significant (age: $b = -0.11$, 95% CI $[-0.26, 0.04]$, $p = 0.16$, education: $b = 0.40$, 95% CI $[-0.43, 1.24]$, $p = 0.35$). No significant differences were found between current and former microdosers ($b = 1.09$, 95% CI $[-1.96, 4.13]$, $p = 0.48$), nor type of substance used ($b = 1.37$, 95% CI $[-2.83, 5.57]$, $p = 0.523$), nor total lifetime number of microdoses ($b = 0.62$, 95% CI $[-0.80, 2.05]$, $p = 0.39$).

Negative emotionality Microdosing predicted lower negative emotionality ($b = -5.78$, 95% CI $[-10.13, -1.43]$, $z(396) = -2.60$, $p = 0.009$, $r = -0.85$), even after controlling for gender, which was also a significant predictor (higher negative emotionality in females, $b = 10.49$, 95% CI $[5.33, 15.65]$, $z(396) = 3.99$, $p < 0.001$, $r = 0.95$). Planned follow-up analysis tested the difference between current and former microdosers and no significant difference existed between the groups ($b = -2.95$, 95% CI $[-7.47, 1.58]$, $p = 0.20$), nor between substance used ($b = -5.18$, 95% CI $[-11.50, 1.15]$, $p = 0.110$), nor any effect of lifetime number of microdoses ($b = -0.25$, 95% CI $[-2.38, 1.89]$, $p = 0.82$) on negative emotionality.

Open-mindedness Microdosing predicted greater open-mindedness ($b = 3.24$, 95% CI $[0.38, 6.10]$, $z(392) = 2.22$, $p = 0.027$, $r = 0.67$), including when controlling for education, which was not significant ($b = 0.08$, 95% CI $[-0.65, 0.81]$, $p = 0.83$). Again there were no significant differences between current and former microdosers ($b = -1.18$, 95% CI $[-4.00, 1.64]$, $p = 0.41$), nor type of substance used ($b = 1.35$, 95% CI

$[-2.61, 5.31]$, $p = 0.506$), nor total lifetime number of microdoses ($b = 0.77$, 95% CI $[-0.55, 2.09]$, $p = 0.26$).

Creativity

Microdosing predicted higher scores on all three creativity facets: on average, responses made by microdosers were more clever ($b = 0.57$, SE = 0.13, $z(423) = 4.25$, $p < 0.001$, $r = 0.15$), more uncommon ($b = 0.50$, SE = 0.15, $z(427) = 3.42$, $p < 0.001$, $r = 0.14$), and more remote ($b = 0.74$, SE = 0.16, $z(425) = 4.49$, $p < 0.001$, $r = 0.20$).

Importance of benefits

Self-reported “importance of benefits” was intended to reflect participants’ broad valuation of microdosing. Counter to H3a/b, no significant differences were found in reported importance of benefits when regressed on lifetime microdoses ($b = 1.01$, 95% CI $[-0.81, 2.82]$, $p = 0.277$) nor frequency of microdosing regardless of explored linear and non-linear relationships (raw: $b = -0.07$, 95% CI $[-0.66, 0.53]$, $p = 0.83$; squared: $b = -0.0004$, 95% CI $[-0.01, 0.01]$, $p = 0.94$; logarithmic: $b = 1.21$, 95% CI $[-2.68, 5.09]$, $p = 0.54$). Counter to H4a/b, there was also no significant difference in the importance of benefits between participants who had previous experience with full-dose classic psychedelics and those who had no such experience ($b = -4.09$, 95% CI $[-11.80, 3.61]$, $p = 0.30$) nor based on the variety and recency of recreational substance use (Polydrug User Experience Index: $b = -0.006$, 95% CI $[-0.26, 0.25]$, $p = 0.96$).

Table 1 Contrast between microdosers and non-microdosers, means with standard deviations and standardized effect-sizes

Variable	Microdoser	Non-microdoser	Effect size <i>d</i> [95% CI]
Age	27.23 (8.94)	26.36 (7.78)	0.1 [−0.04, 0.25]
Education ¹	4.72 (1.72)	4.78 (1.77)	−0.03 [−0.18, 0.11]
SES ²	0.50 (1.33)	0.51 (1.40)	−0.01 [−0.15, 0.14]
Mood—valence	2.33 (4.40)	−0.16 (4.14)	<i>0.58 [0.44, 0.72]</i>
Mood—intensity	−0.08 (2.42)	0.02 (2.40)	−0.04 [−0.18, 0.09]
Dysfunctional attitudes (DAS-17) ³	40.62 (16.28)	49.30 (16.33)	−0.53 [−0.77, −0.29]
Wisdom (BWSS)	66.68 (13.16)	60.05 (12.98)	<i>0.51 [0.27, 0.74]</i>
Negative emotionality (BFI-2)	41.53 (20.06)	48.16 (18.89)	−0.34 [−0.56, −0.11]
Open-mindedness (BFI-2)	76.43 (12.44)	73.33 (13.16)	<i>0.25 [0.02, 0.47]</i>

Italics indicates effect sizes statistically different than zero

¹ Education was coded according to the International Standard Classification of Education (UNESCO Institute for Statistics 2011): ISCED level 0 = early childhood education, 1 = primary education, 2 = lower secondary education, 3 = upper secondary education, 4 = post-secondary non-tertiary education, 5 = short-cycle tertiary education, 6 = bachelor's or equivalent level, 7 = master's or equivalent level, 8 = doctoral or equivalent level

² Socio-economic status (SES) was coded as: −3 = non-working class (casual workers, pensioners, or dependents); −2 = working class (semi-skilled or unskilled manual workers); −1 = skilled working class (skilled manual workers); 0 = lower-middle class (junior managerial, administrative, or professional); 1 = middle class (intermediate managerial, administrative, or professional); 2 = upper-middle class (higher managerial, administrative, or professional); 3 = upper class (royalty or immense heritable wealth)

³ DAS scores have been transformed to the original DAS-17 scale (17–119)

Exploratory analysis

Exploratory comparison of mood measures (valence and intensity, Tables 1 and 2) by Welch's *t* test revealed that microdosers reported significantly more positive valence ($M = 2.33$, $SD = 4.40$) than non-microdosers ($M = -0.16$, $SD = 4.14$; difference: 2.49, 95% CI [1.91 3.07], $t(675) = 8.44$, $p < 0.001$, $r = 0.31$). No differences were found for mood intensity (difference: -0.11 , 95% CI [−0.44 0.22] $p = 0.53$). For valence, current microdosers ($M = 2.93$, $SD = 4.57$) also reported more positive valence than former microdosers ($M = 1.86$, $SD = 4.21$; difference: 1.07, 95% CI [0.35 1.79], $t(533) = 2.92$, $p = 0.004$, $r = 0.13$), but no difference in mood intensity (difference: 0.33, 95% CI [−0.06 0.72], $p = 0.10$).

Table 2 Follow-up analysis of microdosers (current versus former), means with standard deviations and standardized effect-sizes

Variable	Current microdoser	Former microdoser	Effect size <i>d</i> [95% CI]
Age	28.89 (9.71)	25.93 (8.06)	<i>0.33 [0.16, 0.51]</i>
Education	4.83 (1.70)	4.64 (1.73)	0.11 [−0.06, 0.28]
SES	0.48 (1.34)	0.52 (1.32)	−0.03 [−0.2, 0.14]
Mood—valence	2.93 (4.57)	1.86 (4.21)	<i>0.24 [0.08, 0.41]</i>
Mood—intensity	0.10 (2.38)	−0.23 (2.45)	0.14 [−0.03, 0.3]
Dysfunctional attitudes (DAS-17)	39.53 (14.58)	41.53 (17.56)	−0.12 [−0.36, 0.11]
Wisdom (BWSS)	66.09 (12.86)	67.18 (13.42)	−0.08 [−0.32, 0.15]
Negative emotionality (BFI-2)	43.32 (19.98)	39.95 (20.07)	0.17 [−0.06, 0.4]
Open-mindedness (BFI-2)	77.06 (11.91)	75.87 (12.91)	0.09 [−0.13, 0.32]

Italics indicates effect sizes statistically different than zero

Discussion

This is the first pre-registered report on microdosing psychedelics and is intended to inform future lab-based clinical intervention studies. We investigated psychedelic microdosing in online communities and tested pre-registered hypotheses (Anderson et al. 2017) concerning the relationship between experience with microdosing and various mental health and personality variables. Our results suggest a beneficial relationship wherein experience with microdosing is associated with lower dysfunctional attitudes and negative emotionality and higher wisdom, open-mindedness, and creativity. The most popular substances used to microdose were LSD and psilocybin, and no significant differences based on substance were found on our quantitative

measures. The qualitative benefits and drawbacks collected in this survey may yet reveal substance-based effects (Anderson et al. 2018). Hypotheses predicting perceived importance of microdosing from dose-related practices were unsupported and optimal dose scheduling remains an open question. Exploratory analyses revealed that microdosers, especially current microdosers, had more positive emotional valence than non-microdosers, whereas emotional intensity was not significantly different. Taken together, these findings suggest that randomized, placebo-controlled clinical trials (RCTs) of microdosing are warranted to investigate the causal efficacy of microdosing.

Consistent with our hypotheses, microdosing experience was associated with meaningfully lower levels of dysfunctional attitudes. Individuals with higher dysfunctional attitudes maintain a set of disadvantageous beliefs that increase vulnerability to stressors (Jarrett et al. 2012) and high scores are associated with depression (Adler et al. 2015; de Graaf et al. 2009). Also consistent with our hypotheses was the lower negative emotionality seen in microdosers, though the estimated effect was less precise. Tendencies to experience negative emotionality (e.g., anxiety, depression, and emotional volatility) are a robust predictor of mental and physical health problems (Lahey 2009) thus reduced vulnerability is reflected in the lower scores seen in microdosers. Exploratory analysis revealed that microdosers had more positive emotional valence than non-microdosers, linking microdosing to better mood states. While causation cannot be inferred from these results, significant differences were preserved even after controlling for potent covariates, such as gender and history of mental illness, indicating a potentially distinct contribution of microdosing on mental health vulnerability that warrants further study.

Microdosers also had higher wisdom, which is a complex trait (BWSS, Glück et al. 2013). As measured by the BWSS, wisdom is understood to reflect learning from one's mistakes, considering multiple perspectives when facing a situation, being in tune with one's own emotions and the emotions of others, and feeling a sense of connection and unity. Higher scores, as seen in this sample of microdosers, may be associated with cognitive and emotional processing differences including enhanced capacity for perspective taking, resilience in the face of the vicissitudes of life, and increased feelings of engagement and connection. RCT research addressing the relationship between wisdom and microdosing is warranted.

Greater open-mindedness was expected in microdosers compared to controls due to previous studies noting increases in openness following a full-dose of psilocybin (MacLean et al. 2011). These differences were supported, though this effect was relatively weaker than the others. Still, given the findings from full-dose psychedelic studies, future clinical intervention research should continue investigating any causal relationship between open-mindedness and microdosing.

Microdosers were more creative when finding unusual uses for household items. This is consistent with Fredrickson's

(2004) Broaden and Build theory, which suggests a positive relationship between creativity and positive affect, which was also seen in microdosers. Happier, more creative people may be more likely to apply novel modes of thinking in their personal and interpersonal challenges (Fredrickson 2004). Our findings are also consistent with the anecdotal reports that a relationship between microdosing, creativity, and mood exists, but RCTs, ideally with multiple creativity measures, is required.

None of our hypotheses concerning the importance of microdosing benefits and microdosing practices were supported. It is likely that this measure was not sensitive and specific enough; planned analyses of qualitative benefits and drawbacks of microdosing will be explored in a separate report (Anderson et al. 2018). It may be that microdosing frequency is truly unrelated to the subjective valuation of microdosing, but this seems improbable. We suggest that this research question is best addressed in RCT studies focused on specific benefits with experimental manipulation of dose and schedule to determine optimal benefit-specific protocols. Similarly, there is no evidence that outcomes are predicated on prior experience with substances, whether full-dose psychedelics or with a variety of substances. More microdosers had experience with full-doses (69%, $n = 412$) then did not (31%, $n = 182$) and many microdosers (and non-microdosers) had experience with full-dose psychedelics within the month prior to completing the survey. As full-dose psychedelics can have benefits lasting at least a month (Carhart-Harris et al. 2017), this covariate should be formally modeled in future microdosing research designs, which should aim to include both psychedelic-naïve and psychedelic-experienced participants.

Limitations and future directions

The sample is both a strength and a limitation of this study. This sample represents a true community of microdosers with dozens of countries represented; however, countries in the Anglo cultural cluster make up the majority of the sample (> 70%) and participants were predominantly middle class, white, male, and heterosexual. Sampling from online communities, including Reddit, could create a demographic bias; thus, we cannot suggest a definitive epidemiological generalization. Despite this limitation, this sample does inform us about real community practices in an otherwise unstudied population and reflects our sample of interest.

A second limitation of this study is its correlational nature. This cross-sectional design contained no longitudinal component or experimental manipulation and cannot be used to infer causal relationships. Our findings of group-differences do not infer that microdosing caused these differences as some of the measured constructs may even promote an increased willingness to explore microdosing, e.g., open-mindedness. Instead, these findings are intended as a descriptive foundation upon which experimental and clinical studies of psychedelic

microdosing can be designed, exploring the directionality of relationships established in the present study.

To test causal hypotheses concerning microdosing effects, pre-registered randomized placebo-control trials (RCTs) are needed. With random assignment to microdose or placebo, it would be possible to determine whether microdosing causally influences mental health and personality. Following positive causal findings, mechanistic studies could then investigate the observed efficacy in terms of physiological, psychological, and neurobiological changes.

Promisingly, microdosing may prove easier to administer, monitor, and placebo-control in lab settings due to the absence of the intense perceptual shifts induced by full-doses. Microdosing may thus be amenable to designs that could aid in mapping the neural mechanisms behind psychedelic efficacy. Microdosing could also be explored as an adjunct to long-term psychotherapy predicated on the longitudinal cultivation of resilience and insight, a new paradigm that could complement the acutely transformative model underlying high-dose psychedelic psychotherapy (Rosenbaum et al. 2018).

Conclusion

This study provides initial, correlational evidence for mental health and personality benefits associated with microdosing psychedelics. While anecdotal reports of microdosing benefits have existed for some time (Fadiman 2011), this study marks the first formal study of the topic. Additionally, the use of a pre-registered study design sets a precedent for responsible and replicable psychedelic microdosing research. To add depth to the current discussion, a full epidemiological report (Rosenbaum et al. 2018) and a Grounded Theory analysis of qualitative outcomes (Anderson et al. 2018) are forthcoming.

The results of the present study suggest that there is a significant relationship between microdosing experience and measures of mental health and flourishing including lower dysfunctional attitudes and negative emotionality, higher wisdom and open-mindedness, and higher creativity and affect-valence. These findings are the initial evidence that warrants RCTs to directly test safety and therapeutic efficacy. With almost 40,000 users subscribing to the /r/microdosing subreddit and thousands more reading media reports on microdosing, this growing community continues to explore microdosing and its effects. It is our hope that scientific reporting can help to clarify and inform the public about the nature of microdosing's putative effects and that this new paradigm helps shape future psychedelic research. We hope that researchers will draw on our shared resources (<https://osf.io/g5cwy/>) and pre-register studies of their own so that psychedelic science will be built upon strong research practices. Insights from these and other studies will form the backbone of future research into microdosing psychedelics.

Compliance with ethical standards

Human participation was voluntary under informed consent, in accord with the Declaration of Helsinki, and was non-remunerative.

Conflict of interest The authors declare that they have no conflict of interest.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

- Adler AD, Strunk DR, Fazio RH (2015) What changes in cognitive therapy for depression? An examination of cognitive therapy skills and maladaptive beliefs. *Behav Ther* 46(1). Special series: advances in evidence-based intervention and assessment practices for youth with an autism spectrum disorder:96–109. <https://doi.org/10.1016/j.beth.2014.09.001>
- Anderson T, Petranker R, Dinh-Williams L-A (2017) Demography of microdosing community survey. Available at: <https://osf.io/g5cwy/> (accessed 6 July 2018)
- Anderson T, Christopher A, Petranker R, et al. (2018) Benefits and drawbacks of microdosing psychedelics. Manuscript in preparation. Available at: osf.io/g5cwy
- Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PCR, Strassman RJ (2015) Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. *J Psychopharmacol* 29(3): 289–299. <https://doi.org/10.1177/0269881114565144>
- Carbonaro TM, Bradstreet MP, Barrett FS, MacLean KA, Jesse R, Johnson MW, Griffiths RR (2016) Survey study of challenging experiences after ingesting psilocybin mushrooms: acute and enduring positive and negative consequences. *J Psychopharmacol* 30(12): 1268–1278. <https://doi.org/10.1177/0269881116662634>
- Carhart-Harris RL, Roseman L, Bolstridge M, Demetriou L, Pannekoek JN, Wall MB, Tanner M, Kaelen M, McGonigle J, Murphy K, Leech R, Curran HV, Nutt DJ (2017) Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. *Sci Rep* 7(1): 13187. <https://doi.org/10.1038/s41598-017-13282-7>
- de Graaf LE, Roelofs J, Huibers MJH (2009) Measuring dysfunctional attitudes in the general population: the Dysfunctional Attitude Scale (form A) revised. *Cogn Ther Res* 33(4):345–355. <https://doi.org/10.1007/s10608-009-9229-y>
- de Osório FL, Sanches RF, Macedo LR et al (2015) Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report. *Rev Bras Psiquiatr* 37(1):13–20. <https://doi.org/10.1590/1516-4446-2014-1496>
- de Wit H, Phillips TJ (2012) Do initial responses to drugs predict future use or abuse? *Neurosci Biobehav Rev* 36(6):1565–1576. <https://doi.org/10.1016/j.neubiorev.2012.04.005>
- Domínguez-Clavé E, Soler J, Elices M, Pascual JC, Álvarez E, de la Fuente Revenga M, Friedlander P, Feilding A, Riba J (2016) Ayahuasca: pharmacology, neuroscience and therapeutic potential. *Brain Res Bull* 126(Pt 1):89–101. <https://doi.org/10.1016/j.brainresbull.2016.03.002>
- Dos Santos RG, Osório FL, Crippa JAS et al (2016) Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years. *Ther Adv Psychopharmacol* 6(3):193–213. <https://doi.org/10.1177/2045125316638008>
- Fadiman J (2011) *The psychedelic explorer's guide*. Park Street Press, Rochester

- Fredrickson BL (2004) The broaden-and-build theory of positive emotions. *Philos Trans R Soc Lond Ser B Biol Sci* 359(1449):1367–1378. <https://doi.org/10.1098/rstb.2004.1512>
- Glück J, König S, Naschenweng K, Redzanowski U, Dorner L, Straßer I, Wiedermann W (2013) How to measure wisdom: content, reliability, and validity of five measures. *Front Psychol* 4:405. <https://doi.org/10.3389/fpsyg.2013.00405>
- Griffiths RR, Johnson MW, Richards WA, Richards BD, McCann U, Jesse R (2011) Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. *Psychopharmacology* 218(4):649–665. <https://doi.org/10.1007/s00213-011-2358-5>
- Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, Cosimano MP, Klinedinst MA (2016) Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. *J Psychopharmacol* 30(12):1181–1197. <https://doi.org/10.1177/0269881116675513>
- Grinspoon L, Bakalar JB (1979) *Psychedelic drugs reconsidered*. Basic Books, New York
- Gunnarsson M, Gustavsson P, Tengström A et al (2008) Personality traits and their associations with substance use among adolescents. *Personal Individ Differ* 45:356–360. <https://doi.org/10.1016/j.paid.2008.05.004>
- Halpern JH, Pope HG (1999) Do hallucinogens cause residual neuropsychological toxicity? *Drug Alcohol Depend* 53(3):247–256. [https://doi.org/10.1016/S0376-8716\(98\)00129-X](https://doi.org/10.1016/S0376-8716(98)00129-X)
- Hardaway R, Schweitzer J, Suzuki J (2016) Hallucinogen use disorders. *Child Adolesc Psychiatr Clin N Am* 25(3):489–496. <https://doi.org/10.1016/j.chc.2016.03.006>
- Harrington DM (1975) Effects of explicit instructions to "be creative" on the psychological meaning of divergent thinking test scores. *J Pers* 43(3):434–454
- Jarrett RB, Minhajuddin A, Borman PD, Dunlap L, Segal ZV, Kidner CL, Friedman ES, Thase ME (2012) Cognitive reactivity, dysfunctional attitudes, and depressive relapse and recurrence in cognitive therapy responders. *Behav Res Ther* 50(5):280–286. <https://doi.org/10.1016/j.brat.2012.01.008>
- Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR (2014) Pilot study of the 5-HT_{2A}R agonist psilocybin in the treatment of tobacco addiction. *J Psychopharmacol* 28(11):983–992. <https://doi.org/10.1177/0269881114548296>
- Johnson MW, Griffiths RR, Hendricks PS, Henningfield JE (2018) The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. *Neuropharmacology*. <https://doi.org/10.1016/j.neuropharm.2018.05.012>
- Kometer M, Pokorny T, Seifritz E, Volleinweider FX (2015) Psilocybin-induced spiritual experiences and insightfulness are associated with synchronization of neuronal oscillations. *Psychopharmacology* 232(19):3663–3676. <https://doi.org/10.1007/s00213-015-4026-7>
- Krebs TS, Johansen P-Ø (2013) Psychedelics and mental health: a population study. *PLoS One* 8(8):e63972. <https://doi.org/10.1371/journal.pone.0063972>
- Lahey BB (2009) Public health significance of neuroticism. *Am Psychol* 64(4):241–256. <https://doi.org/10.1037/a0015309>
- Leonard A (2015) How LSD microdosing became the hot new business trip. In: *Rolling stone*. Available at: <https://www.rollingstone.com/culture/culture-news/how-ld-microdosing-became-the-hot-new-business-trip-64961/> (accessed 9 July 2018)
- MacLean KA, Johnson MW, Griffiths RR (2011) Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. *J Psychopharmacol* 25(11):1453–1461. <https://doi.org/10.1177/0269881111420188>
- Martinotti G, Santacrose R, Pettorruso M, et al (2018) Hallucinogen Persisting Perception Disorder: Etiology, Clinical Features, and Therapeutic Perspectives. *Brain Sciences* 8:47. <https://doi.org/10.3390/brainsci8030047>
- Matejka J, Glueck M, Grossman T, et al. (2016) The effect of visual appearance on the performance of continuous sliders and visual analogue scales. In: *Proceedings of the 2016 CHI conference on human factors in computing systems*, New York, NY, USA, 2016, pp. 5421–5432. CHI '16. ACM. <https://doi.org/10.1145/2858036.2858063>
- Moreno FA, Wiegand CB, Taitano EK, Delgado PL (2006) Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. *J Clin Psychiatry* 67(11):1735–1740
- Rosenbaum D, Weissman C, Hapke E, et al. (2018) Microdosing psychedelic substances: demographics, psychiatric comorbidities, and comorbid substance use. Manuscript in preparation. Manuscript submitted for publication. Available at: osf.io/g5cwy
- Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, Mennenga SE, Belsler A, Kalliontzi K, Babb J, Su Z, Corby P, Schmidt BL (2016) Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. *J Psychopharmacol* 30(12):1165–1180. <https://doi.org/10.1177/0269881116675512>
- Silvia PJ (2011) Subjective scoring of divergent thinking: examining the reliability of unusual uses, instances, and consequences tasks. *Think Skills Creat* 6(1):24–30. <https://doi.org/10.1016/j.tsc.2010.06.001>
- Silvia PJ, Winterstein BP, Willse JT, Barona CM, Cram JT, Hess KI, Martinez JL, Richard CA (2008) Assessing creativity with divergent thinking tasks: exploring the reliability and validity of new subjective scoring methods. *Psychol Aesthet Creat Arts* 2(2):68–85. <https://doi.org/10.1037/1931-3896.2.2.68>
- Solon O (2016) Under pressure, Silicon Valley workers turn to LSD microdosing. *Wired UK*, 24 August. Available at: <http://www.wired.co.uk/article/ld-microdosing-drugs-silicon-valley> (accessed 9 July 2018)
- Soto CJ, John OP (2017) The next Big Five Inventory (BFI-2): Developing and assessing a hierarchical model with 15 facets to enhance bandwidth, fidelity, and predictive power. *Journal of Personality and Social Psychology* 113:117–143. <https://doi.org/10.1037/pspp0000096>
- Strassman RJ (2016) DMT: the spirit molecule: a doctor's revolutionary research into the biology of near-death and mystical experiences. Inner Traditions, Rochester
- Terracciano A, Löckenhoff CE, Crum RM, Bienvenu OJ, Costa PT (2008) Five-factor model personality profiles of drug users. *BMC Psychiatry* 8:22. <https://doi.org/10.1186/1471-244X-8-22>
- Trull TJ, Sher KJ (1994) Relationship between the five-factor model of personality and Axis I disorders in a nonclinical sample. *J Abnorm Psychol* 103(2):350–360. <https://doi.org/10.1037/0021-843X.103.2.350>
- UNESCO Institute for Statistics (2011) International standard classification of education (ISCED) 2011. Available at: <http://uis.unesco.org/sites/default/files/documents/international-standard-classification-of-education-isced-2011-en.pdf>
- van Amsterdam J, Opperhuizen A, van den Brink W (2011) Harm potential of magic mushroom use: a review. *Regul Toxicol Pharmacol* 59(3):423–429. <https://doi.org/10.1016/j.yrtph.2011.01.006>
- Waldman A (2017) *A really good day: how microdosing made a mega difference in my mood, my marriage, and my life*, 1st edn. Knopf, New York
- Weissman AN, Beck AT (1978) Development and validation of the dysfunctional attitude scale. Paper presented at the Annual meeting of the Association for the Advanced Behavior Therapy, Chicago, November.